Dr Ivan Horak, CEO & Founder of Tikva Allocell received the Lifetime Achievement Award at APCGTEA 2024

Dr. Ivan D. Horak, CEO and Founder of Tikva Allocell (Tikva), received the Lifetime Achievement Award at APCGTEA 2024 in recognition for his contributions and leadership in the cell and gene therapy.
SINGAPORE – 13 Sep 2024 – Dr. Ivan D. Horak, CEO and Founder of Tikva Allocell (Tikva), a pre-clinical stage company targeting solid tumors via proprietary allogeneic EBV specific T cell platform, received the Lifetime Achievement Award at the Asia Pacific Cell & Gene Therapy Excellence Awards 2024 in recognition for his contributions and leadership in the cell and gene therapy space.

"It is an honor to receive this award, I truly appreciate it. It is a recognition for the effort of the numerous scientists that I have the great honor to work with in moving the field of cell and gene therapy forward. I am also encouraged by the trajectory of the field and the commitment and tenacity of the scientists in this space. I am confident that we will be able to make significant improvement to patient health."

Ivan D. Horak - CEO and Founder, Tikva Allocell
Dr. Ivan Horak has extensive experience in the global pharmaceutical industry. He was former Chief Scientific and Medical Officer at Tessa Therapeutics. Prior to that, he was Head of Global R&D and Chief Scientific and Medical Officer at Symphogen. He also served as President of R&D at Enzon Pharmaceuticals. Dr. Horak has held leadership positions in various pharmaceutical companies as well as at the National Cancer Institute (NCI). During his career, Dr. Horak has successfully led a number of FDA new drug applications. Dr. Horak is a member of the American Association for Cancer Research (AACR), American Society of Clinical Oncology (ASCO), American Society of Hematology (ASH) and European Society of Medical Oncology (ESMO). He also published over 90 scientific articles and book chapters. Dr. Ivan Horak is a board-certified medical oncologist. 

About Tikva Allocell

Tikva Allocell Pte Ltd is a late preclinical stage biotech company headquartered in Singapore. Our cell therapy platform is an off-the-shelf CAR-T therapy, utilizing highly specific second-generation allogeneic T cells prepared from the blood of Epstein-Barr virus (EBV)-positive healthy individuals. Our approach exploits the intrinsic properties of Virus-Specific T cells (VSTs), enhanced by IP-protected novel repurposing strategies to enhance cell performance and safely target patients with solid tumors including gastric, prostate and triple negative breast cancers.

For more information on Tikva, please visit www.tikvaallocell.com.

Investors and Media Contact

Wilson W. Cheung

FINANCIAL Advisor
Share the Post:

Related Posts

The multifarious role of SerpinB9 armoring

CAR-T cell therapy has revolutionized cancer treatment, but its efficacy against solid tumors remains limited due to challenges like poor CAR-T cell in-vivo survival. Tikva’s engineered SB9 EBVST platform will not only address a major resistance mechanism axis but also opens doors to more effective CAR T cell therapies for solid tumors.

Read More